A Greek Observational Study on Relapse Rate and Sustained Virological Response in Naive CHC [chronic hepatitis C] Patients, Treated With Pegylated Interferon Alpha-2b and Ribavirin in Daily Clinical Practice
Latest Information Update: 10 May 2022
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2b/ribavirin (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme; Merck Sharp & Dohme Corp.; Schering-Plough
- 04 Oct 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 04 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jun 2010 Planned end date changed from Jun 2010 to Dec 2010 as reported by ClinicalTrials.gov.